Eagle Pharmaceuticals Inc (EGRX) has released an update to notify the public and investors about a regulation fd disclosure.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Eagle Pharmaceuticals, Inc. announced an update to its bendamustine intellectual property portfolio through a press release on January 18, 2024. This information, provided in a press release attached to their Current Report, is not considered “filed” under the Securities Exchange Act of 1934 nor is it to be incorporated into other SEC filings by the company.
For further insights into EGRX stock, check out TipRanks’ Stock Analysis page.